Eli Lilly Targets Crohn’s Disease With New Combo Trial That Could Extend Its IBD Franchise

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.

Eli Lilly and Company (LLY) is launching a Phase 2 trial titled “A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared With Mirikizumab in Adults With Moderately to Severely Active Crohn’s Disease.” The goal is to see if adding LY4395089 to mirikizumab improves safety and benefit versus mirikizumab alone in adults with tough-to-treat Crohn’s disease.

The study tests two approaches. One group gets mirikizumab alone, while the other gets a new oral drug, LY4395089, together with mirikizumab, to see if the combo can control symptoms better and faster.

Mirikizumab is already an advanced anti-inflammatory antibody given by IV first, then by under-the-skin injection for responders. LY4395089 is an oral FXR agonist aimed at reducing gut inflammation, so the pair could offer a more complete way to manage Crohn’s disease if the combo proves safe and more effective.

The trial is interventional and randomized, meaning participants are assigned by chance to each treatment arm. It uses a parallel design with no blinding, so both patients and doctors know which treatment is used, and the main goal is to treat disease rather than just observe outcomes.

The study is active but listed as “not yet recruiting,” with the first submission and latest update both on March 16, 2026. The planned duration is about 62 weeks per participant, so key Phase 2 readouts will likely fall at least a year after enrollment begins, setting expectations for when data could start to influence valuation.

As an early-stage asset, LY4395089 is not yet in models, but positive signals could support LLY’s inflammatory bowel disease franchise and extend mirikizumab’s lifecycle. For investors, the trial underlines Lilly’s push to deepen its immunology portfolio alongside its weight-loss and diabetes engines, while competitors in IBD such as AbbVie and Johnson & Johnson may face added longer-term pressure if the combo succeeds.

This Phase 2 trial of LY4395089 plus mirikizumab in Crohn’s disease is newly posted and not yet recruiting, and investors can track ongoing updates and details on the ClinicalTrials portal.

To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.